Welcome to our dedicated page for MAXCYTE SEC filings (Ticker: MXCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MAXCYTE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MAXCYTE's regulatory disclosures and financial reporting.
River Global Investors LLP reports beneficial ownership of 834,100.00 MaxCyte, Inc. shares, representing 0.7786% of the company’s equity, with sole voting and dispositive power over this stake as of July 31, 2026.
This position follows an extraordinary corporate transaction in which the FCA approved the change in control and proposed acquisition of River Global Holdings Limited. After this approval, Liontrust Investment Partners LLP assumed responsibility for the River Global Investors ICVC and ICAV funds, and voting rights attached to approximately 4.3% of MaxCyte shares transferred from River Global Investors to Liontrust. Approximately 0.8% voting rights remain with River Global Investors and will be transferred at a later stage.
BlackRock, Inc. reports its institutional ownership position in MaxCyte, Inc. common stock. As of June 30, 2026, BlackRock beneficially owned 1,402,591 shares of MaxCyte common stock, representing 1.3% of the outstanding class. BlackRock has sole voting power and sole dispositive power over all 1,402,591 shares, with no shared voting or dispositive power.
The filing notes that various underlying clients have the right to receive dividends or sale proceeds from these shares, but no single person has an interest in more than five percent of MaxCyte’s total outstanding common shares. This amendment reflects BlackRock’s status as a holder of 5 percent or less of the class.
Johnston John Joseph reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director John Joseph Johnston received 30,421 restricted stock units, each representing one share of common stock, as part of his annual non-employee director grant. He also received a stock option for 49,579 shares at $1.13 per share, expiring in 2036. The RSUs vest on June 17, 2027, subject to continued service, bringing his direct common stock holdings to 201,581 shares.
Hemrajani Rekha reported acquisition or exercise transactions in this Form 4 filing.
MAXCYTE, INC. director Rekha Hemrajani reported equity awards consisting of restricted stock units and stock options. She received 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with a strike price of $1.13 per share, expiring on June 16, 2036. The annual grant for non-employee directors vests on June 17, 2027, subject to her continuous service, bringing her direct common stock holdings to 70,314 shares.
MAXCYTE, INC. director Stanley C. Erck received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one common share, and an option for 49,579 shares at an exercise price of $1.13 per share, expiring on June 16, 2036. The RSUs vest on June 17, 2027, subject to his continued service, and his direct common stock holdings after the grant total 428,749 shares.
MAXCYTE, INC. director Douglas Richard reported awards of restricted stock units and stock options as part of his compensation. He acquired 30,421 RSUs, each representing one future share of common stock, and 49,579 stock options to buy common shares at $1.13 per share.
The annual grants were made under the company’s equity grant policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, assuming he continues to serve. After the RSU grant, his direct common stock holdings total 260,998 shares.
MAXCYTE director Cynthia Collins received new equity awards. On June 17, 2026, she was granted 30,421 restricted stock units, each representing one future share of common stock, and a stock option for 49,579 shares at an exercise price of $1.13 per share, expiring in 2036. Following the grant, she directly holds 111,310 shares of common stock, and the RSUs vest on June 17, 2027 if she continues serving as a director.
MAXCYTE, INC. director Brooke William W received equity awards consisting of common stock and stock options. He was granted 30,421 shares of Common Stock in the form of restricted stock units, each representing a right to one share. These RSUs vest on June 17, 2027, if he continues serving as a non-employee director under the company’s Equity Grant Policy. He was also granted stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share, expiring on June 16, 2036. Following these awards, he directly holds 181,300 shares of Common Stock.
MAXCYTE, INC. director Patrick J. Balthrop received equity-based compensation in the form of restricted stock units and stock options. He was granted 30,421 RSUs, each representing one share of common stock, and 49,579 stock options with an exercise price of $1.13 per share. The RSU grant was made under the company’s equity grant policy for non-employee directors and is scheduled to vest on June 17, 2027, contingent on his continued service. Following the RSU grant, Balthrop directly holds 80,998 shares of common stock. The stock options, which are also directly held, are exercisable into 49,579 shares of common stock and are scheduled to expire on June 16, 2036.
MAXCYTE, INC. director Yasir B. Al-Wakeel received equity awards as part of his annual non-employee director compensation. He was granted 30,421 shares of Common Stock in the form of restricted stock units, plus stock options for 49,579 shares at an exercise price of $1.13 per share.
The RSUs and option grant were made under the company’s Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, contingent on his continued service. Following the RSU grant, he directly owns 80,998 shares of Common Stock.